Abstract 2310P
Background
The rapid proliferation of cancer cells leads to abnormal vascularization, creating a hypoxic tumor core in most advanced solid tumors. Recent studies have shown that hypoxia is associated with poor prognosis in cancer patients. Tumor aggressiveness is driven by hypoxia, which confers resistance to many conventional cancer therapies. In the present study, we propose that oxygen nanobubbles can reduce the hypoxic effect on the epithelial-to-mesenchymal transition (EMT) and prevent migration and invasion in non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).
Methods
Using the sonic cavitation method, we have developed a method to generate bulk oxygen nanobubbles (ONBs) with dipalmitoyl phosphatidylcholine (DPPC) lipid and quantitate mean diameter and number density through nanoparticle tracking analysis and insight. We have treated A549 lung adenocarcinoma and MDA-MB-231 triple-negative breast cancer cell lines with 1% oxygen and ONB. We have also checked its preventive role in the zebrafish tumor xenograft model. We have measured HIF-1a and EMT expression markers by immunoblot and qPCR analysis. Moreover, we have used the 4T1 BALB/c mice tumor xenograft model for further confirmation.
Results
ONB promotes HIF-1α hydroxylation and its proteasomal degradation in hypoxic cancer cells. ONBs treated A549 and MDA-MB-231 cancer cells and an adult zebrafish A549 tumor xenografts showed the downregulation of TGF-β and VEGFA expression at the transcriptional and translational levels, which also led to upregulation of epithelial genes like E-cadherin with down-regulation of mesenchymal genes like N cadherin, Vimentin, Fibronectin. ONB treatment significantly affects cancer cell migration. Also, liposomal ONB administrated 4T1 BALB/c breast tumor xenograft model showed similar results.
Conclusions
ONBs reduce HIF-1 mediated epithelial to mesenchymal transition (EMT) controlled by TGF-b and VEGFA and prevent cellular migration and invasion in solid tumors, particularly NSCLC and TNBC. In conclusion, targeted administration of ONB could be a better therapeutic approach to inhibit the hypoxic detrimental effect, which helps to increase the efficacy of anticancer treatments.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Department of Science and Technology (DST) Project, India (DSTSERB- ECR/2016/000288Department of Science and Technology (DST) Project, India (DSTSERB- DST (Department of Science and Technology) Project India, ECR/2016/000288.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2294P - Whole genome sequencing to define the germline-somatic interaction in young-onset lung cancer
Presenter: Jaclyn LoPiccolo
Session: Poster session 08
2295P - Pan-cancer prevalence of MET fusions and clinical response to MET- targeted therapy
Presenter: Morana Vojnic
Session: Poster session 08
2296P - SGLT2 i dapagliflozin reduces NF-kB expression in heart and kidneys of preclinical models exposed to doxorubicin through MYd-88 and NLRP3 pathways
Presenter: Nicola Maurea
Session: Poster session 08
2297P - Gene co-expression networks capture the potential pathogenesis and progression of upper tract urothelial cancer
Presenter: Tingting Fu
Session: Poster session 08
2298P - Feasibility of ex vivo drug sensitivity testing in urothelial cancer: EVITA trial
Presenter: Mathijs Scholtes
Session: Poster session 08
2299P - Mebendazole enhances the anticancer effect of irinotecan and check-point inhibitor in vitro and in vivo
Presenter: Sharmineh Mansoori
Session: Poster session 08
2300P - Clonal hematopoiesis of indeterminate potential (CHIP) in patients with advanced NSCLC treated with immune checkpoint blockers (ICB) as monotherapy: Analysis of the PREMIS study
Presenter: Julieta Rodriguez
Session: Poster session 08
2301P - Combining cancer patient spatial transcriptomics and bulk RNA-Seq data to drive insights into NSCLC
Presenter: Julia Bischof
Session: Poster session 08
2302P - Efficacy assessment of targeted and immunotherapies for personalised treatment of melanoma using 2D and 3D ex-vivo assays
Presenter: Md Marufur Rahman
Session: Poster session 08
2303P - Protein functional interpretation of gene variants observed in clinical next-generation sequencing (NGS) for pleural mesothelioma
Presenter: Ferdinando Cerciello
Session: Poster session 08